基于TCGA研究细胞坏死相关基因对肝细胞癌患者预后的影响*

doi:10.3969/j.issn.1672-5069.2022.06.028

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (6): 869-872.doi: 10.3969/j.issn.1672-5069.2022.06.028

基于TCGA研究细胞坏死相关基因对肝细胞癌患者预后的影响^*

石青春, 潘立民, 布凡, 王永强, 关睿骞

150040 哈尔滨市黑龙江中医药大学(石青春,布凡,王永强);附属第二医院医务科(潘立民);附属第二医院针灸推拿科(关睿骞)

收稿日期:2022-03-03 出版日期:2022-11-10 发布日期:2022-11-22
通讯作者: 潘立民,E-mail:2621902358@qq.com
作者简介:石青春,男,28岁,硕士研究生。E-mail:1390766341@qq.com
基金资助:
^*国家自然科学基金资助项目(编号:81572939)

TCGA-based study of cell necrosis-related genes as prognostic indicators in patients with hepatocellular carcinoma

Shi Qingchun, Pan Limin, Bu Fan, et al.

Heilongjiang University of Chinese Medicine,Harbin 150040,Heilongjiang Province, China

Received:2022-03-03 Online:2022-11-10 Published:2022-11-22

摘要/Abstract

摘要： 目的研究细胞坏死相关基因对肝细胞癌(HCC)患者预后的影响。方法自癌症基因组图谱TCGA数据库下载HCC患者mRNA水平数据及其对应的临床资料。应用LASSO Cox回归在TCGA文件中构建多坏死相关基因预后模型。结果在单因素Cox回归分析中,23个细胞坏死相关差异水平基因与预后生存相关(P<0.05);构建一个显著相关的6个细胞坏死相关基因的预后模型,发生高风险组总体生存期显著低于低风险组(P<0.01);多因素Cox回归分析风险评分符合独立的预后因子标准(P<0.O1);对差异水平基因进行富集分析(GO/KEGG)和单样本基因集富集分析(ssGSEA),发现差异基因与免疫通路显著相关(P<0.05)。结论通过6个细胞坏死相关基因构建的预后模型可以用于预测HCC患者的预后,或许能为HCC患者的临床治疗提供参考。

关键词: 肝细胞癌, 细胞坏死, TCGA数据库, 预后

Abstract: Objective The purpose of this study was to investigate the impact of cell necrosis-related genes on prognosis of patients with hepatocellular carcinoma (HCC). Methods The mRNA data of patients with HCC and the clinical data of corresponding patients were downloaded from the Cancer Genome Atlas TCGA database. The polynecrosis-related gene prognostic models were constructed in TCGA files by using LASSO Cox regression. Results by univariate Cox regression analysis, 23 cell necrosis-related differentially expressed genes were associated with prognostic survival (P < 0.05); in this protocol, a significantly correlated prognostic model of 6 cell necrosis-related genes was constructed; the patients were divided into two groups according to the threshold of risk, and the overall survival in patients with high risk was significantly reduced as compared to in those with low risk (P<0.01); meanwhile, by multivariate Cox regression analysis, the risk score met the criteria for independent prognostic factors (P<0.01); the enrichment analysis (GO/KEGG) and one-sample gene set enrichment analysis (ssGSEA) were performed based on differentially gene levels, and the differential genes were found to be correlated to immune pathways (P<0.05). Conclusion The prognostic model we constructed by 6 cell necrosis-related genes could be applied to predict independently the prognosis of patients with HCC and provide a reference for the clinical management appropriately.

Key words: Hepatocellular carcinoma, Cell necrosis, TCGA database, Prognosis

石青春, 潘立民, 布凡, 王永强, 关睿骞. 基于TCGA研究细胞坏死相关基因对肝细胞癌患者预后的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 869-872.

Shi Qingchun, Pan Limin, Bu Fan, et al.. TCGA-based study of cell necrosis-related genes as prognostic indicators in patients with hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2022, 25(6): 869-872.

参考文献

[1] 周新民,丁小鹏. 基础肝病治疗在原发性肝癌综合治疗中的重要作用.实用肝脏病杂志,2021,24(1),4-6.
[2] Llovet J M,Kelley R K,Villanueva A,et al. Hepatocellular carcinoma. Nat Rev Dis Prim,2021, 7(1):6.
[3] D'arcy M S.Cell death: a review of the major forms of apoptosis, necrosis and autophagy.Cell Biology Int, 2019,43(6):582-592.
[4] Pasparakis M,Vandenabeele P.Necroptosis and its role in inflammation.Nature,2015,517(7534):311-320.
[5] Simon N,Friedman J,Hastie T,et al.Regularization paths for Cox's proportional hazards model via coordinate descent.J Statist Softw,2011,39(5):1-13.
[6] Tibshirni R.The lasso method for variable selection in the Cox model.Statist Med,1997,16(4):385-395.
[7] 赵艺,卢秉久.基于TCGA数据库分析肝细胞癌组织UCK2、PRIM1和DNTM1基因水平对患者预后的影响.实用肝脏病杂志,2021,24(5):729-732.
[8] Horn-Ghetko D,Krist D T,Prabu J R,et al.Ubiquitin ligation to F-box protein targets by SCF-RBR E3-E3 super-assembly.Nature,2021,590(7847):671-676.
[9] Vanden Berghe T,Linkermann A,Jouan-lanhouet S,et al.Regulated necrosis: the expanding network of non-apoptotic cell death pathways.Nat Rev Mol Cell Biol,2014,15(2):135-147.
[10] Lamkanfi M,Dixit V M.Mechanisms and functions of inflammasomes.Cell,2014,157(5):1013-1022.
[11] Gautheron J,Vucur M,Reisinger F,et al.A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis.EMBO Mol Med,2014,6(8):1062-1074.
[12] Roychowdhury S,Mcmullen M R,Pisano S G,et al.Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury.Hepatology (Baltimore, Md),2013,57(5):1773-1783.
[13] Gong Y,Fan Z,Luo G,et al.The role of necroptosis in cancer biology and therapy.Mol Cancer,2019,18(1):100.
[14] Yang T B,Yi F,Liu W F,et al.Identification of hsa_circ_0039053 as an up-regulated and oncogenic circRNA in hepatocellular carcinoma via the miR-637-mediated USP21 activation.J Cancer,2020,11(23):6950-6959.
[15] Pannu J,Belle J I,Förster M,et al.Ubiquitin specific protease 21 is dispensable for normal development, hematopoiesis and lymphocyte differentiation.PLoS One,2015,10(2):e0117304.
[16] Duran A,Hernandez E D,Reina-campos M,et al.p62/SQSTM1 by binding to vitamin D receptor inhibits hepatic stellate cell activity, fibrosis, and liver cancer.Cancer cell,2016,30(4):595-609.
[17] Shi W,Feng L,Dong S,et al.FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.Cell Commun Sign,2020,18(1):100.
[18] Morales J,Li L,Fattah F J,et al.Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.Crit Rev Eukary Gene Express,2014,24(1):15-28.
[19] Wang C,Tang H,Geng A,et al.Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors.Proc Nat Acad Sci USA,2020,117(42):26356-26365.
[20] Tsai C H,Chen Y J,Yu C J,et al.SMYD3-mediated H2A.Z.1 methylation promotes cell cycle and cancer proliferation.Cancer Res,2016,76(20):6043-6053.

基于TCGA研究细胞坏死相关基因对肝细胞癌患者预后的影响^*

TCGA-based study of cell necrosis-related genes as prognostic indicators in patients with hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	贺潇瑾, 李丹, 周青, 欧阳静, 田玉球, 谭英征. L02细胞乙型肝炎病毒X蛋白和SOCS-1基因水平研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 772-775.
[2]	李荣, 曹晶晶, 李晶, 潘峰. 慢加急性/亚急性乙型肝炎肝衰竭患者发病诱因及影响临床转归因素分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 832-835.
[3]	沈亦亮, 沈冬元, 陈永莹, 江凯, 朱逸明, 葛尚. 肝硬化患者肝内LR-3类结节恶变风险评估及预测模型的建立^*[J]. 实用肝脏病杂志, 2022, 25(6): 836-839.
[4]	朱海艳, 范晓棠. 肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证[J]. 实用肝脏病杂志, 2022, 25(6): 848-852.
[5]	张耀辉, 郑章增, 高星, 张亚利. 超声造影时间-强度曲线诊断肝硬化患者肝内小结节病灶价值研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 861-864.
[6]	郑希彦, 杜飞, 林志群, 李瑞曦, 周正, 张广权, 周红, 何方平, 史宪杰. 肝细胞癌进展:代谢综合征相关危险因素研究[J]. 实用肝脏病杂志, 2022, 25(6): 877-880.
[7]	高正兴, 李广欣, 宋春青. 癌组织M6A甲基转移酶样蛋白3水平对手术切除后接受索拉非尼治疗的肝细胞癌患者预后的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 885-888.
[8]	崔坡, 董士铭, 南月敏. 慢性基础肝病对新型冠状病毒肺炎患者结局的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 905-908.
[9]	王倩, 李文莉, 王兵, 吴茂盛, 魏芳芳. 70例登革热并发肝损伤患者临床特征和预后因素分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 645-648.
[10]	刘艳, 沈宇, 张茜. 60例药物性肝损伤患者临床特征和转归分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 649-652.
[11]	王明强, 牛垚飞, 王生锋. 慢加急性乙型肝炎肝衰竭患者血清聚集素水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 677-680.
[12]	吴桐, 张巧丽, 齐雪维. 肝细胞癌RNA结合蛋白功能和预后价值系统分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 693-697.
[13]	杜联江, 李京涛, 崔杰. 肝细胞癌癌组织caspase-3和DcR3蛋白及SNHG12 mRNA水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 706-709.
[14]	李清汉, 甄作均, 何尹韬. 肝动脉化疗栓塞联合射频消融和免疫靶向治疗术后复发的肝细胞癌患者近远期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 714-717.
[15]	施莹, 柏根基, 孙阳. 多模态MRI对肝硬化增生性结节与小肝癌的鉴别诊断价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 722-725.